SpringWorks Therapeutics Inc

NASDAQ:SWTX   3:17:18 PM EDT
71.86
-1.24 (-1.70%)
Products, Strategic Combinations, Regulatory

Springworks Announces Collaboration With Children’S Oncology To Conduct A Phase 2 Clinical Trial Of Nirogacestat

Published: 09/16/2020 10:45 GMT
SpringWorks Therapeutics Inc (SWTX) - Springworks Therapeutics Announces Collaboration With Children’s Oncology Group to Conduct a Phase 2 Clinical Trial of Nirogacestat in Pediatric Patients With Desmoid Tumors and Reports Publication of Nirogacestat Case Series in Pediatric/young Adult Desm.
Springworks Therapeutics Inc - Investigators Reported Clinical Responses in All Four Patients Treated With Nirogacestat.
Springworks Therapeutics - No Grade 3 Or 4 Adverse Events Reported.